After a period with a paucity of new drug regimens, GO was re-examined at lower doses, and further studies demonstrated that a dose of 3 mg/m2 was safe and effective, motivating the FDA to re-approve GO for newly diagnosed and R/R CD33+ AML [66,70]. Here, CD33 is linked to acute myeloid leukemia.